CTLA4 and metastatic melanoma: Ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody, approved by the FDA in 2011, demonstrates prolonged survival in patients with metastatic melanoma [21].